Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Tumbleweed67on Jun 14, 2010 1:30am
540 Views
Post# 17185076

RE: Statistically insignificant hypothesis

RE: Statistically insignificant hypothesisGreat post there bigwalleye! Something else there that caught my eye that I missed previously is their burn rate is only $400k/Q for "basic operations". So all this talk about them running out of money by the end of the year is BS. Where the money will be needed is obviously to start the next trials. Perhaps we could see a financing to conduct the TBI trial on their own, but phase III stroke is going to need a partner for sure.

TW
Bullboard Posts